XLV250411C142500
- 0.07
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
Catalyst Watch: Spotlight on Tesla, Alphabet Earnings, AACR Drug Data, and Global PMI Reports
A Congress Member Sold Up To $120K In AbbVie Stock: Here's What You Need To Know
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Leading And Lagging Sectors For April 18, 2025
Netflix, UnitedHealth, Novo Nordisk, Tesla And Trump Media: Why These 5 Stocks Are On Investors' Radars Today
The "miracle weight loss drug" has entered the oral era. Will Eli Lilly and Co become the king of weight loss medications?
Wall Street Analysts generally believe that the GLP-1 weight loss medication field is transitioning from injectable forms to more convenient oral forms, and Eli Lilly and Co has already gained an early lead. This fierce, multi-year competition has clearly shown a winner; at least for now, Eli Lilly and Co has been crowned by the market as the new king in the realm of GLP-1 drugs.
Weight stocks have faced a sharp decline, while the Dow Jones, known as the "most resilient" index in the U.S. stock market, has fallen against the trend.
The Dow Jones uses a price-weighted method, which means that price changes in high stock price shares have a greater impact on the index than those in low stock price shares. Overnight, the largest weighted stock, UnitedHealth, plummeted 18%, dragging the Dow down by 1.2%, while the S&P 500 Index rose by as much as 0.6%. Media compilation data shows that since 1954, instances where the Dow fell by 1% or more while the S&P rose at least 0.5% have only occurred once.
Express News | 'FDA Fires Most Negotiators For Pharma User Fee Talks, Sources Say' - Reuters Exclusive
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
SA Asks: What's the Best Weight-loss Drug Stock Right Now?
Trump Said to Have Privately Discussed Terminating Fed Chair Powell for Months
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
Assessing Merck & Co: Insights From 9 Financial Analysts
Why Did Lilly Data for Oral Obesity Drug Boost Structure and Metsera?
The Dow Is Lower After Its Largest Component, UnitedHealth, Declined Over 20% on Reduced FY25 Outlook.
UnitedHealth Plunges 23% and Its Fall Sent Ripples Across the ETF Landscape
Live On CNBC, Steve Weiss Announces Bought More United Health
Nvidia, Meta And 3 More Stocks Are This Strategist's Top Buys: Here's Why
Earnings Call Summary | UnitedHealth(UNH.US) Q1 2025 Earnings Conference